spacer
home > ebr > winter 2018 > regional requirements
PUBLICATIONS
European Biopharmaceutical Review

Regional Requirements

Globalisation has affected the life sciences and pharmaceutical industries just as much as it has other sectors, and a growing push to standardise submission formats has opened market opportunities for many life sciences companies. The common technical document (CTD) has already become the de facto standard in many regions as more and more countries respond to the ICH’s mission of greater harmonisation around the “interpretation and application of technical guidelines and requirements for pharmaceutical product registration” (1).

Regional Regulatory Climate

Today, most countries – either directly or through regional agencies – are members of the ICH or observe its guidelines. Through ongoing consultations between ICH and regulatory agencies, most regions of the world either have adopted – or are working towards meeting – the ICH guidelines centred on the areas of quality, safety, efficacy and multidisciplinary regulatory issues.

Even though most countries and regions are still paper-based, the push towards electronic submission is growing, and more countries are adopting or at least exploring electronic CTD initiatives. However, regional differences remain, even where strong alliances and a structured approach to regulatory submissions exist.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kimty Bui-Van is head of regulatory and pharma services practice at ProductLife Group, where she is responsible for the coordination of all regulatory affairs activities undertaken on behalf of clients. She draws on nearly 20 years of experience in regulatory affairs, both within the industry and as a consultant, to guide clients through all aspects of regulatory affairs, including initial submissions, variations, renewals and product lifecycle management. Kimty has been instrumental in establishing a transformative approach to managing affiliate regulatory and pharmacovigilance activities globally on behalf of clients. 
spacer
Kimty Bui-Van
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement